Latest Advances in Lung Cancer Research

The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki, a new drug for treating HER2-positive unresectable or metastatic breast cancer in adults.

Cancer death rates in the U.S. have dropped 33% since 1991, saving 3.8 million lives, but disparities and challenges in certain cancers remain.

Lung cancer rates are increasing among Asian American women, according to a new study published in the journal Cancer.

Weill Cornell Medicine scientists create a mouse model to study lung cancer’s transformation into deadly SCLC.

David P. Carbone, MD, PhD, sought to transform lung cancer care and did it—but didn’t anticipate the personal journey it would put him on.

Rising lung cancer in young, non-smoking women puzzles doctors; research on potential pregnancy link and new causes is crucial for prevention and early detection.

Recent studies confirm genomic testing for NSCLC enhances treatment choices and survival, advocating for its standardization in clinical practice.

A novel nanoparticle vaccine halts lung cancer spread in mice by training the immune system to attack tumor cells, showing promise for post-surgery cancer prevention.

UCLA researchers received a $6 million grant to refine a liquid biopsy blood test for early, accurate lung cancer detection and treatment guidance.

Johnson & Johnson’s Rybrevant shows comparable efficacy to AstraZeneca’s Tagrisso in advanced NSCLC, suggesting potential as an initial treatment option.

Experimental gene therapy drug HPN328 is being tested with Tecentriq in a trial to enhance immune response against small cell lung cancer.

Adding atezolizumab and tiragolumab to chemotherapy may improve survival in extensive stage small cell lung cancer, with further research needed.